检索结果-南通市图书馆

ERCP in acute pancreatitis:What takes place in routine clinical practice?

World Journal of Gastrointestinal Endoscopy 2010年第9期2卷 308-313页

作者： Armando Gabbrielli Raffaele Pezzilli Generoso Uomo Alessandro Zerbi Luca Frulloni Paolo De Rai Laura Castoldi Guido Costamagna Claudio Bassi Valerio Di Carlo Department of Surgical and gastroenterological Sciences University of Verona Department of Digestive Diseases and Internal Medicine S.Orsola-Malpighi Hospital Department of Internal Medicine Department of Surgery Humanitas Hospital Department of Emergency Surgery Fondazione IRCCS MaggioreMangiagalli and Regina Elena Hospital Digestive Endoscopy Unit "Agostino Gemelli" University HospitalCatholic University of Rome Rome 00100 Italy Department of Surgery University Vita e Salute

AIM:To evaluate the data from a survey carried out in Italy regarding the endoscopic approach to acute pancreatitis in order to obtain a picture of what takes place after the release of an educational project on acute pancreatitis sponsored by the Italian association for the Study of the ***:Of the 1 173 patients enrolled in our survey,the most frequent etiological category was biliary forms(69.3%) and most patients had mild pancreatitis(85.8%).RESULTS:344/1 173(29.3%) underwent endoscopic retrograde cholangiopancreatography(ERCP).The mean interval between the onset of symptoms and ERCP was 6.7 ± 5.0 d;only 89 examinations(25.9%) were performed within 72 h from the onset of *** main indications for ERCP were suspicion of common bile duct stones(90.3%),jaundice(44.5%),clini cal worsening of acute pancreatitis(14.2%) and cho langitis(6.1%).Biliary and pancreatic ducts were visua lized in 305 patients(88.7%) and in 93 patients(27.0%) *** success rate in obtaining a cholangio gram was statistically higher(P = 0.003) in patients with mild acute pancreatitis(90.6%) than in patients with severe disease(72.2%).Biliary endoscopic sphinc terotomy was performed in 295 of the 305 patients(96.7%) with no difference between mild and severe disease(P = 0.985).ERCP morbidity was 6.1% and mortality was 1.7%;the mortality was due to the complications of acute pancreatitis and not the endoscopic ***:The results of this survey,as with those carried out in other countries,indicate a lack of compliance with the guidelines for the indications for interventional endoscopy.

关键词： Acute pancreatitis Epidemiology,Endoscopic retrograde cholangiopancreatography Data collection

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

卒中介入治疗培训指南：国际多学会共识文件

引用

国际脑血管病杂志 2017年第5期25卷 396-399页

作者： Lavine SD Cockroft K Hoh B Bambakidis N Khalessi AA Woo H Riina H Siddiqui A Hirsch JA Chong W Rice H Wenderoth J Mitchell P Coulthard A Signh TJ Phatorous C Khangure M Klurfan P ter Brugge K Iancu D Gunnarsson T Pongpech S Rodesch G Soderman M Taylor A Krings T Orbach D Picard L Suh DC Zheng HQ Jansen O Muto M Szikora I Pierot L Brouwer P Gralla J Renowden S Andersson T Fiehler J Turjman F White P Januel AC Spelle L Kulcsar Z Chapot R Biondi A Dima S Taschner C Szajner M Krajina A Sakai N Matsumaru Y Yoshknura S Ezura M Fujinaka T Iihara K Ishii A Higashi T Hirohata M Hyodo A Ito Y Kawanishi M Kiyosue H Kobayashi E Kobayashi S Kuwayama N Matsumoto Y Miyachi S Murayama Y Nagata I Nakahara I Nemoto S Niimi Y Oishi H Satomi J Satow T Sugiu K Tanaka M Terada T Yamagami H Diaz O Lylyk P Jayaraman MV Patsalides A Gandhi CD Lee SK Abruzzo T Albani B Ansari SA Arthur AS Baxter BW Bulsara KR Chen M Almandoz JE Fraser JF Heck DV Hetts SW Hussain MS Klucznik RP Leslie-Mawzi TM Mack WJ McTaggart RA Meyers PM Mocco J Prestigiacomo CA Pride GL Rasmussen PA Starke RM Sunenshine PJ Tarr RW Frei DF Pabo M Nogueira RG Zaidat OO Jovin T Linfante I Yavagal D Liebeskind D Novakovic R Pongpech S 许岩孙瑞郭芮兵 From the American association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Rolling Meadows IL USA American Society of Neuroradiology (ASNR) Oak Brook IL USA Asian Australasian Federation of lnterventional and Therapeutic Neuroradiology (AAFITN) Bali Indonesia Australian and New Zealand Society of Neuroradiobgy-Conjomt Committee for Recognition of Training in Interventional Neuroradiology (CCINR) representing the RANZCR (ANZSNR) ANZAN and NSA Sydney Australia Canadian Interventional Neuro Group (CING) Edmonton AB Canada World Federation of Interventional and Therapeutic Neuroradiology (WFITN) Gold Coast Australia European Society of Neuroradiology (ESNR) Milan Italy European Society of Minimally Invasive Neurologic Therapy (ESMINT) Nice France japanese Society for Neuroendovascular therapy (JSNET) Okayama Japan Sociedad Ibero Latino Americana de Neuroradiologica (SILAN) Cartagena Colombia Society of Neurolnterventional Surgery (SNIS) Washington DC USA Society of Vascular and Interventional Neurology (SVIN) Brooklyn NY USA 南京大学医学院附属金陵医院(南京军区南京总医院)神经内科 210002 解放军第一0一医院(无锡太湖医院)神经内科无锡214004

1背景缺血性卒中是全球人口死亡和残疾的首要原因。很多急性大血管闭塞（emergent large vesselocclusion，ELVO）患者都会遗留长期残疾。事实上，这些颅内大动脉闭塞经常会导致大面积脑损伤，进而造成患者死亡或严重致残。

关键词：缺血性卒中培训指南介入治疗文件学会国际血管闭塞动脉闭塞

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Consensus of primary care in acute pancreatitis in Japan

引用

World Journal of Gastroenterology 2006年第21期12卷 3314-3323页

在日本的尖锐胰腺炎的发生正在增加并且每百万张人口从 187 ～ 347 个盒子。盒子命运是 0.2% 为对温和中等，并且 9.0% 为在在 2003 的日本的严重尖锐胰腺炎。在日本的胰腺炎的专家做了与尖锐胰腺炎在病人的早管理集中于实际方面的这个... 详细信息

在日本的尖锐胰腺炎的发生正在增加并且每百万张人口从 187 ～ 347 个盒子。盒子命运是 0.2% 为对温和中等，并且 9.0% 为在在 2003 的日本的严重尖锐胰腺炎。在日本的胰腺炎的专家做了与尖锐胰腺炎在病人的早管理集中于实际方面的这个文件。尖锐胰腺炎和严厉层化的正确诊断应该为尖锐胰腺炎的诊断用标准在所有病人被做并且多，因素得分系统尽早由胰的难处理的疾病的研究委员会求婚了。与尖锐胰腺炎诊断的所有病人应该在医院里被管理。血压监视，脉搏和呼吸率，体温，时时尿的体积，和血氧饱和水平在如此的病人的管理是必要的。早精力旺盛的静脉内的水和具有最前的重要性稳定循环动力学。有鸦片剂的足够的疼痛地势也是重要的。在严重尖锐胰腺炎，在一个早阶段的抗菌素的预防静脉内的管理被推荐。一旦尖锐胰腺炎的诊断被证实，朊酶禁止者的管理应该被开始。如果没有肠塞痛并且胃肠的流血的清楚的症状，从早舞台用非肠道的营养喂的肠内的联合被推荐。有严重尖锐胰腺炎的病人应该尽早被转移到 ICU 执行象朊酶的连续地区性的动脉的注入那样的特殊措施禁止者和抗菌素，和连续牙齿过敏过滤。日本政府为难处理的疾病作为关于措施的研究的工程之一为严重尖锐胰腺炎盖住医疗保健开销。

关键词：急性胰腺炎蛋白酶日本病理机制

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w

引用

Chinese Journal of Cancer 2016年第12期35卷 735-742页

作者： Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim Gastrointestinal Cancer Center Sano HospitalHyogo 655-0031Japan. State Key Laboratory of Oncology in South China Department of Medical OncologyCollaborative Innovation Center for Cancer MedicineSun Yat-sen Univer-sity Cancer CenterGuangzhouGuangdong 510060P.R.China. Depart-ment of Clinical Oncology Aichi Cancer Center HospitalNagoya 464-8681Japan. Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 135-710South Korea. Department of Biomedical Statistics and Bioinformatics Graduate School of MedicineKyoto UniversityKyoto 606-8501Japan. Gastrointestinal Medical Oncology Division National Cancer Center HospitalTokyo 104-0045Japan. Depart-ment of Surgical Specialties Graduate SchoolTokyo Medical and Dental UniversityTokyo 113-8519Japan. Department of Gastrointestinal Medical Oncology National Hospital Organization Shikoku Cancer CenterMatsuy-ama 791-0280Japan. Department of Surgical Oncology The University of TokyoTokyo 113-0033Japan. Department of Surgery Tokyo Metropoli-tan Komagome HospitalTokyo 113-8677Japan. Division of Gastrointestinal Oncology Shizuoka Cancer CenterShizuoka 411-8777Japan. Department of Internal Medicine Seoul National University HospitalSeoul 110-744South Korea. Department of Gastrointestinal Oncology The First People's Hospital of FoshanFoshanGuangdong 528000P.R.China. Department of Inter-nal Medicine Yonsei University College of MedicineSeoul 120-752South Korea. Department of Medical Oncology The Sixth Ailiated HospitalSun Yat-sen UniversityGuangzhouGuangdong 510655P.R.China. Depart-ment of Hematology-Oncology Chonnam National University Medical SchoolGwangju 519-809South Korea. Department of Digestive Oncology Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China. Department of Internal Medicine Seoul National University Bundang Hos-pitalSeoul National University College of MedicineSeongnam 463-707South Korea. Department of Medical Oncology Union Hospital of Tongji Medical College

Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in japanese ***: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than ***: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence fo

关键词： Metastatic colorectal cancer Randomized phase Ⅲ clinical trial XELIRI Bevacizumab Second-line therapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction

引用

World Journal of Gastroenterology 2016年第14期22卷 3793-3802页

作者： Naoki Sasahira Tsuyoshi Hamada Osamu Togawa Ryuichi Yamamoto Tomohisa Iwai Kiichi Tamada Yoshiaki Kawaguchi Kenji Shimura Takero Koike Yu Yoshida Kazuya Sugimori Shomei Ryozawa Toshiharu Kakimoto Ko Nishikawa Katsuya Kitamura Tsunao Imamura Masafumi Mizuide Nobuo Toda Iruru Maetani Yuji Sakai Takao Itoi Masatsugu Nagahama Yousuke Nakai Hiroyuki Isayama Department of Gastroenterology JCHO Tokyo Takanawa HospitalTokyo 108-8606Japan Department of Gastroenterology Graduate School of MedicineThe University of TokyoTokyo 113-8655Japan Department of Gastroenterology Saitama International Medical CenterSaitama Medical UniversitySaitama 350-1298Japan Department of Gastroenterology and Hepatology Saitama Medical University International Medical CenterSaitama 350-8550Japan Department of Gastroenterology Kitasato UniversityKanagawa 252-0375Japan Department of Gastroenterology Jichi Medical UniversityTochigi 329-0498Japan Department of Gastroenterology Tokai UniversityKanagawa 259-1193Japan Department of Gastroenterology Asahi General HospitalChiba 289-2511Japan Department of Internal Medicine Japanese Red Cross Ashikaga HospitalTochigi 326-0843Japan Department of Gastroenterology Kimitsu Central HospitalChiba 292-8535Japan Department of Gastroenterology Yokohama City University Medical CenterKanagawa 232-0024Japan Department of Gastroenterology Showa University Northern Yokohama HospitalKanagawa 242-0032Japan Department of Gastroenterology Saitama City HospitalSaitama 336-8522Japan Department of Gastroenterology Ageo Central General HospitalSaitama 362-8588Japan Division of Gastroenterology Department of MedicineShowa University School of MedicineTokyo 142-8666Japan Department of Gastroenterology Toranomon HospitalTokyo 105-0001Japan Department of Gastroenterology Gunma UniversityGunma 371-0034Japan Department of Gastroenterology Mitsui Memorial HospitalTokyo 101-8643Japan Division of Gastroenterology and Hepatology Department of Internal MedicineToho University Ohashi Medical CenterTokyo 153-0044Japan Department of Gastroenterology Chiba UniversityChiba 260-0856Japan Department of Gastroenterology Tokyo Medical UniversityTokyo 160-0023Japan Department of Gastroenterology Showa University Fujigaoka HospitalKanagawa 227-8501Japan

AIM: To determine the optimal method of endoscopic preoperative biliary drainage for malignant distal biliary ***: Multicenter retrospective study was conducted in patients who underwent plastic stent(PS) or nasobiliary catheter(NBC) placement for resectable malignant distal biliary obstruction followed by surgery between January 2010 and March 2012. Procedurerelated adverse events, stent/catheter dysfunction(occlusion or migration of PS/NBC, developmentof cholangitis, or other conditions that required repeat endoscopic biliary intervention), and jaundice resolution(bilirubin level association with the time to jaundice resolution and PS/NBC dysfunction using competing risk regression ***: In total, 419 patients were included in the study(PS, 253 and NBC, 166). Primary cancers included pancreatic cancer in 194 patients(46%), bile duct cancer in 172(41%), gallbladder cancer in three(1%), and ampullary cancer in 50(12%). The median serum total bilirubin was 7.8 mg/d L and 324 patients(77%) had ≥ 3.0 mg/d L. During the median time to surgery of 29 d [interquartile range(IQR), 30-39 d]. PS/NBC dysfunction rate was 35% for PS and 18% for NBC [Subdistribution hazard ratio(SHR) = 4.76; 95%CI: 2.44-10.0, P < 0.001]; the pig-tailed tip was a risk factor for PS dysfunction. Jaundice resolution was achieved in 85% of patients and did not depend on the drainage method(PS or NBC).CONCLUSION: PS has insufficient patency for preoperative biliary drainage. Given the drawbacks of external drainage via NBC, an alternative method of internal drainage should be explored.

关键词： endoscopic preoperative biliary drainage Malignant distal biliary obstruction Periampullary cancer P

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：